Who is sponsoring NCT04587960?

NCT04587960 is sponsored by Dr.Jhuma Biswas.

What drugs are being tested in NCT04587960?

Interventions in NCT04587960: Delayed primary closure of skin incision in Caesarean section in experimental group, Primary closure of skin incision in Caesarean section in active comparator group.

What condition does NCT04587960 study?

NCT04587960 studies Cesarean Wound Disruption, Cesarean Section; Infection.

Is NCT04587960 still recruiting?

NCT04587960 is currently completed. Last updated 1 October 2021.

Last reviewed 2021-10-01 · How we verify

NCT04587960

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Delayed Primary Closure of Skin in Emergency Caesarean Section

Completed NA Last updated 1 October 2021

What this trial tests

NA trial testing Delayed primary closure of skin incision in Caesarean section in experimental group in Cesarean Wound Disruption in 70 participants. Completed in 15 June 2021.

Timeline

1 March 2021

Primary endpoint
15 June 2021

15 June 2021

Quick facts

Lead sponsor	Dr.Jhuma Biswas
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	70
Start date	1 March 2021
Primary completion	15 June 2021
Estimated completion	15 June 2021
Sites	1 location across India

Drugs / interventions tested

Delayed primary closure of skin incision in Caesarean section in experimental group
Primary closure of skin incision in Caesarean section in active comparator group

Conditions studied

Cesarean Wound Disruption — all drugs for Cesarean Wound Disruption →
Cesarean Section; Infection — all drugs for Cesarean Section; Infection →

Sponsor

Dr.Jhuma Biswas

Who can join

Adults 21 to 40, female only, with Cesarean Wound Disruption or Cesarean Section; Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Pregnant mothers requiring emergency cs with history of ruptured membranes would be allocated randomly into two groups in an aim to study the comparative outcome of different methods of skin closure namely primary and delayed primary closure on the incidence of wound infections requiring secondary closures and to detect the associated risk factors increasing chance of surgical site infections.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Usefulness of delayed primary closure in unplanned caesarean section to reduce surgical site infection in a resource-poor high population country: a randomised controlled trial.
Biswas J, Dasgupta S, Datta M, Sanyal P, et al · · 2025 · PMID 40077938 · DOI 10.4274/jtgga.galenos.2024.2024-7-1

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04587960 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dr.Jhuma Biswas
Last refreshed: 1 October 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04587960.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing